Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, Pei Jye Voon et al.|Molecular Cancer Therapeutics|2023Cited by 60
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort BXiuning Le, Paul K. Paik, Luis Paz‐Ares et al.|Cell Reports Medicine|2023Cited by 18
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)Eun Joo Kang, KK Lee, Yaewon Yang et al.|ESMO Open|2024Cited by 10